This is the first gene therapy for AADC deficiency to receive US regulatory approval and the first that can be administered directly to the brain.

The panels assess genes with strong disease links and clinical management guidelines, but the firm offers limited-evidence genes as an add-on option.

The pharmaceutical distributor has launched InspiroGene, a business unit offering logistics and other support for ...

NEW YORK – Syros Pharmaceuticals said on Tuesday that its retinoic acid receptor-alpha agonist tamibarotene, which it was testing in combination with azacitidine in patients newly diagnosed with ...